This application seeks to develop a multi-platform clinical decision support system (CDSS) in pulmonary arterial hypertension (PAH) for physicians, PHORA (Pulmonary Hypertension Outcomes Risk Assessment), which can be used to: (a) guide therapeutic decisions and (b) optimize clinical trial design. We will achieve this goal by utilizing clinical trial data from several large databases of completed trials in PAH, an ongoing PAH registry (REVEAL), as well as observational sessions with physicians. The proposed aims co- create the CDSS with a multi-disciplinary group of specialties including: biomedical engineering, advanced PAH physicians, computer science (machine learning/data mining), human computer interaction, and allied health care experts. Our intention is to engage all stakeholders to achieve consensus and thereby assure the acceptance of PHORA into practice. Successful completion of this project will lay the foundation for a prospective, multi-center trial in which PHORA will be evaluated with respect to long-term patient outcomes. The ultimate aim is to disseminate this resource so as to improve the efficiency, efficacy, and cost- effectiveness of this treatment for PAH.
Pulmonary arterial hypertension (PAH) is a rapidly progressive fatal disease for which there are few therapeutic options. Understanding how to predict clinical responses to available therapeutics would be a significant clinical advance in treating this disease by permitting tailored, targeted and effective first line therapies. Our continued studies seek to develop and validate a decision support tool for predicting survival in PAH, which will allow the scientific community and eventually patients a means to choose appropriate specific therapies based on individual risks and patient choices in order to improve survival and quality of life for our patients.